<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03298542</url>
  </required_header>
  <id_info>
    <org_study_id>CR108354</org_study_id>
    <secondary_id>2017-000225-12</secondary_id>
    <secondary_id>CNTO148DML1001</secondary_id>
    <nct_id>NCT03298542</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes</brief_title>
  <official_title>A Phase 1b Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of golimumab in
      children, adolescents, and young adults with pre-symptomatic stage 2 type 1 diabetes mellitus
      (T1D).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">July 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Infections</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Infections</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Study Treatment Injection Site Reactions</measure>
    <time_frame>Up to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78</measure>
    <time_frame>Week 52 to Week 78</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Golimumab</measure>
    <time_frame>Through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Antibodies to Golimumab</measure>
    <time_frame>Through Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pre-Symptomatic Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1: Golimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a SC matching placebo to golimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.</description>
    <arm_group_label>Group 1: Golimumab</arm_group_label>
    <other_name>SIMPONI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to golimumab.</description>
    <arm_group_label>Group 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is positive for at least 2 of the following diabetes-related autoantibodies obtained
             at study screening: Glutamic acid decarboxylase-65 (GADA-65) Autoantibodies,
             Insulinoma-associated 2 Autoantibodies (IA-2A), Zinc Transporter-8 (ZnT8), Islet Cell
             Cytoplasmic Autoantibodies (ICA), or Insulin Autoantibodies (IAA)

          -  Has a plasma glucose of 7.8 to 11.0 millimoles per liter (mmol/L) (140 to 199
             milligrams per deciliter (mg/dL)) at the 120-minute timepoint of a 2-hour(h)-oral
             glucose tolerance test (OGTT), OR have a plasma glucose of greater than (&gt;) 200 mg/dL
             (&gt; 11.1 mmol/L) at the 30, 60, or 90 minute timepoint of a 2h-OGTT OR have a
             hemoglobin A1c (HbA1c) greater than or equal to (&gt;=) 5.7 percent (%) but less than (&lt;)
             6.5% ([&gt;=] 32 to 48 millimoles per moles [mmol/mol]) evaluated at screening

          -  Is medically stable on the basis of physical examination, medical history, laboratory
             results, and vital signs performed at screening

          -  If a woman of childbearing potential must have a negative highly sensitive serum test
             (beta-human chorionic gonadotropin) at screening and a negative urine pregnancy test
             at the Week 0 visit

          -  Must be up-to-date or have initiated catch up vaccines with routine age-appropriate
             immunizations and have received vaccines, or at least initiated vaccine series and
             have a completion plan, that are recommended for immune suppressed individuals
             according to current local recommendations before the first dose of study treatment

        Exclusion Criteria:

          -  Has a current or prior diagnosis of diabetes mellitus (Type 1, Type 2, or gestational)
             or meet the metabolic criteria diagnostic of diabetes mellitus obtained at screening
             including: hemoglobin A1c (HbA1c) greater than or equal to 6.5 (%) (48 mmol/mol), or
             fasting plasma glucose (&gt;=) 7.0 mmol/L (126 mg/dL) (fasting: no intake &gt;= 8 hours), or
             plasma glucose &gt;= 11.1 mmol/L (200 mg/dL) 2 hours post OGTT, or random plasma glucose
             &gt;= 11.1 mmol/L (200 mg/dL) in those with symptoms consistent with hyperglycemia crisis

          -  Has a presence or history of malignancy

          -  Has an immune deficiency syndrome (for example, severe combined immunodeficiency
             syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic
             granulomatous disease), or bone marrow or organ transplantation, or a disease
             associated with lymphopenia

          -  Has other autoimmune diseases (for example, rheumatoid arthritis (RA), polyarticular
             juvenile idiopathic arthritis (pJIA), psoriatic arthritis (PsA), ankylosing
             spondylitis (AS), multiple sclerosis, celiac disease, systemic lupus erythematosus)
             excluding clinically stable autoimmune thyroiditis whether treated or untreated

          -  Has active infections, is prone to infections or has chronic, recurrent or
             opportunistic infectious disease, including but not limited to, chronic renal
             infection, chronic chest infection, sinusitis, recurrent urinary tract infection,
             Pneumocystis carinii, aspergillosis, latent or active granulomatous infection,
             histoplasmosis, or coccidioidomycosis or an open, draining, or infected non healing
             skin wound or ulcer

          -  Has a clinically active infection with Epstein-Barr virus (EBV) or an EBV polymerase
             chain reaction (PCR) viral load serology of &gt;= 10,000 copies per milliliter (mL) at
             study screening

          -  Has a clinically active infection with cytomegalovirus (CMV) or a CMV PCR viral load
             serology of &gt;= 10,000 copies per mL at study screening

          -  Is infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or
             hepatitis C virus (HCV) or at screening tests positive for HIV, HBV, or HCV

          -  Has any of the following tuberculosis (TB) screening criteria: a history of latent or
             active TB prior to screening; signs or symptoms suggestive of active TB upon medical
             history and/or physical examination; recent close contact (within 3 months) with a
             person with known or suspected active TB; a positive QuantiFERON-TB Gold test result
             at screening, the participant should be excluded from the study; a chest radiograph
             taken within 3 months prior to the first administration of study treatment read by a
             qualified radiologist consistent with current, active TB or old, inactive TB

          -  Has a current or prior use of any type and form of exogenous insulin or
             oral/intravenous (IV) antihyperglycemic treatment

          -  Has known or suspected intolerance or hypersensitivity to human proteins, antibody
             fragments, or monoclonal antibodies, including golimumab or its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Denver-Colorado Barbara Davis Center, University of Colorado SOM Pediatric Endocrinology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oulu University Hosp. - Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>SE 58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital/Skåne</name>
      <address>
        <city>Lund/Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108354</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

